跳转至内容
Merck
CN

356M-1

Cytokeratin 5 & 6 (D5 & 16B4) Mouse Monoclonal Antibody

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
D5 & 16B4, monoclonal
Application:
IHC (p)
Citations:
10
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

D5 & 16B4, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (356M-14), vial of 0.5 mL concentrate (356M-15), bottle of 1.0 mL predilute (356M-17), vial of 1.0 mL concentrate (356M-16), bottle of 7.0 mL predilute (356M-18)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

isotype

IgG1

control

mesothelioma

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic

Gene Information

human ... KRT5(3852)

General description

Anti-CK 5 & 6 positivity is seen in 65% to 100% of epithelioid mesotheliomas, in 0% to 19% of lung adenocarcinomas, and in 22% to 80% of serous carcinoma of the ovary and peritoneum. Keratin 5 & 6 expression in lung adenocarcinoma is not common, and when it occurs, the reaction is usually confined to small focal areas or scattered cells. The most probable cause of this finding is the presence of squamous differentiation of lung adenocarcinoma. Anti-CK 5 & 6 positivity has been useful in recognizing squamous cell carcinoma of the skin. Less than 10% of carcinomas of the breast, colon, and prostate stain positively for this marker. Anti-CK 5 & 6 has also been used successfully as a myoepithelial cell marker in the prostate and breast to determine malignancy. Anti-CK 5 & 6 is a useful marker to distinguish lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma within a panel including antibodies against TTF-1, Napsin A, p63, SOX-2, desmocollin3, and desmoglein3.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note


IVD

IVD

IVD

RUO

Other Notes

Cytokeratin 5 & 6 Positive Control Slides, Product No. 356S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


法规信息

监管及禁止进口产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

诊断性免疫组化是一系列用于识别组织异常、建立预后并提示治疗方式的技术。其基本原理是一种抗原-抗体结合反应,利用酶或荧光染料来标记抗体,呈现出组织或组织切片中特定抗原的位置和分布。

Diagnostic immunohistochemistry overview highlights its importance in cancer diagnosis and detecting infectious diseases in modern clinical pathology.


Magali Lacroix-Triki et al.
Virchows Archiv : an international journal of pathology, 442(6), 548-554 (2003-04-25)
Previous studies have shown that basal-type cytokeratins (CKs) can distinguish usual ductal hyperplasia (UDH) from the spectrum of atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Indeed, expression of these CKs is weak
Peiguo G Chu et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 15(1), 6-10 (2002-01-18)
Cytokeratin 5/6 (CK 5/6) immunoreactivity has been observed in the vast majority of cases of malignant mesothelioma but only rarely in pulmonary adenocarcinomas. Thus, CK 5/6 has been used to distinguish malignant mesothelioma from pulmonary adenocarcinoma. However, the utility of
Neil A Abrahams et al.
American journal of clinical pathology, 120(3), 368-376 (2003-09-25)
We evaluated the sensitivity and specificity of cytokeratin (CK) 5/6 for distinguishing foci of atrophy from prostatic adenocarcinoma with and without previous hormonal adjuvant therapy and observed the intensity and pattern of staining in mimickers of prostatic adenocarcinoma (basal cell



全球贸易项目编号

货号GTIN
356M-170841683138341
356M-140841683138310
356M-150841683138327
356M-160841683138334
356M-16-RUO04061836533533
356M-180841683138358